Literature DB >> 28844723

Cocontraction measured with short-range stiffness was higher in obstetric brachial plexus lesions patients compared to healthy subjects.

Galia V Anguelova1, Erwin de Vlugt2, Alistair N Vardy2, Erik W van Zwet3, J Gert van Dijk4, Martijn J A Malessy5, Jurriaan H de Groot6.   

Abstract

We suggest short range stiffness (SRS) at the elbow joint as an alternative diagnostic for EMG to assess cocontraction. Elbow SRS is compared between obstetric brachial plexus lesion (OBPL) patients and healthy subjects (cross-sectional study design). Seven controls (median 28years) and five patients (median 31years) isometrically flexed and extended the elbow at rest and three additional torques [2.1,4.3,6.4Nm] while a fast stretch stimulus was applied. SRS was estimated in silico using a neuromechanical elbow model simulating the torque response from the imposed elbow angle. SRS was higher in patients (250±36Nm/rad) than in controls (150±21Nm/rad, p=0.014), except for the rest condition. Higher elbow SRS suggested greater cocontraction in patients compared to controls. SRS is a promising mechanical alternative to assess cocontraction, which is a frequently encountered clinical problem in OBPL due to axonal misrouting.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Activation ratio; Erb’s palsy; Motor misrouting; Obstetric brachial plexus lesion; Short-range stiffness

Mesh:

Year:  2017        PMID: 28844723     DOI: 10.1016/j.jbiomech.2017.08.015

Source DB:  PubMed          Journal:  J Biomech        ISSN: 0021-9290            Impact factor:   2.712


  1 in total

1.  Effectiveness and safety of early intramuscular botulinum toxin injections to prevent shoulder deformity in babies with brachial plexus birth injury (POPB-TOX), a randomised controlled trial: study protocol.

Authors:  Christelle Pons; Dauphou Eddi; Gregoire Le Gal; Marc Garetier; Douraied Ben Salem; Laetitia Houx; Franck Fitoussi; Nathaly Quintero; Sylvain Brochard
Journal:  BMJ Open       Date:  2019-09-30       Impact factor: 2.692

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.